BPI and Deloitte to Co-Present at CBI’s 3rd Annual GTN Summit, November 20, 2014 – Philadelphia
Deloitte has teamed with BPI to co-present at CBI’s 3rd annual GTN. The subject of their presentation is “GTN and Risk Mitigation – Are Your GTN Capabilities Exposing Your Company to Unacceptable Financial and Regulatory Risk?” A snapshot of their presentation follows: “The dollar value significance of gross-to-net adjustments in the Life Sciences Industry varies by entity and product type, and can represent a significant percentage of gross sales. In the three-year period between 2009-2011, gross-to-net adjustments represented anywhere from 10% to 23% of gross sales for certain pharma manufacturers. How can your company mitigate the risk of error in these estimates and their respective assumptions? How can you ensure that the right data has been assembled, calculated and accurately reported? How can quarterly “surprises” be avoided? In this presentation, you will hear about how to address issues covering the end-to-end gross-to-net process, enabling decisions that Improve accuracy and integrity of financial reporting.”
Being a co-founder of this annual event with BPI having made two previous GTN Best Business Practices presentations, this year’s Deloitte – BPI presentation will be a ‘note-taker.”
If you are unable to attend this GTN Summit presentation, please email George Thompson at email@example.com for a copy.